Silverarc Capital Management LLC Buys Shares of 10,000 Gilead Sciences, Inc. (NASDAQ:GILD)

Silverarc Capital Management LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the biopharmaceutical company's stock, valued at approximately $924,000.

Other large investors also recently bought and sold shares of the company. Westside Investment Management Inc. increased its position in shares of Gilead Sciences by 3.5% in the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock valued at $2,249,000 after buying an additional 917 shares in the last quarter. SkyView Investment Advisors LLC grew its stake in Gilead Sciences by 5.4% in the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock valued at $711,000 after acquiring an additional 435 shares during the period. Pine Valley Investments Ltd Liability Co purchased a new stake in Gilead Sciences in the 3rd quarter worth $209,000. World Investment Advisors LLC raised its position in Gilead Sciences by 33.6% during the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock worth $2,180,000 after acquiring an additional 6,535 shares during the period. Finally, Arvest Bank Trust Division purchased a new position in Gilead Sciences during the third quarter valued at $9,661,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GILD shares. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Friday. Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday. Finally, Wells Fargo & Company increased their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $108.42.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the transaction, the chief financial officer now owns 171,223 shares of the company's stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,540,875. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 2.8 %

NASDAQ GILD traded down $2.98 during trading on Friday, reaching $103.17. 14,207,970 shares of the company's stock were exchanged, compared to its average volume of 7,526,289. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The stock has a market cap of $128.46 billion, a P/E ratio of 278.84, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a 50 day moving average price of $109.21 and a two-hundred day moving average price of $98.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.73 by $0.08. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. During the same period in the prior year, the company posted ($1.32) earnings per share. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.06%. Gilead Sciences's dividend payout ratio is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.